Levetiracetam ER is under clinical development by AgeneBio and currently in Phase III for Mild Cognitive Impairment. According to GlobalData, Phase III drugs for Mild Cognitive Impairment does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Levetiracetam ER LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Levetiracetam ER overview
Levetiracetam ER (AGB-101) is under development for the treatment of amnestic mild cognitive impairment (aMCI) due to Alzheimer’s dementia and psychosis. The drug candidate is once-daily, extended-release capsule and tablet formulation of levetiracetam administered through oral route. It acts by targeting synaptic vesicle protein (SV2A) ligand.
AgeneBio is a pharmaceutical company that develops therapies for psychiatric and neurological diseases. The company’s therapy is targeted to prevent neurodegeneration and preserve and restore cognitive function for unserved patients. Its lead candidate AGB101 is under phase 3 of clinical trials for the treatment of mild cognitive impairment (aMCI) and can delay progression to Alzheimer’s dementia and can target hippocampus overactivity. AgeneBio’s other pipeline product is GABAA alpha5 a small molecule program is being developed for the treatment of aMCI, autism and schizophrenia, among others. The company partners with Johns Hopkins University and leading research centers worldwide. AgeneBio is headquartered in Baltimore, Maryland, the US.
For a complete picture of Levetiracetam ER’s drug-specific PTSR and LoA scores, buy the report here.